6 While 239 drugs containing Sitagliptin, the active ingredient of DPP-4 diabetes treatment Januvia, will be registered for benefit on the 2nd of next month, six existing supplementary items will be deleted from the benefits list. It is interpreted that five items were excluded from the medical care benefit due to the newly created negotiation process. According to the industry on the 23rd, six supplementary items among sitagliptin generics will be deleted from the benefit list on the 1st of next month.

These items were listed before June 2020, when the provisional registration system disappeared. The provisional listing system is a system in which generics approved by the Ministry of Food and Drug Safe